Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›MGTX›AAV2hAQP1

AAV2hAQP1

Ensayo de MeiraGTx Holdings plc en Squamous Cell Head and Neck Cancer · Radiation Induced Xerostomia · Salivary Hypofunction (del registro, en inglés).

Fase
Fase 1
Estado
Completado
Participantes
17
previstos
Centros
1
Fin del objetivo primario
ago 2026
fecha real

Título oficial en el registro (en inglés): Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en may 2015.

De principio a fin

  1. Empieza el ensayo (may 2015)
  2. Lectura de resultados ago 2026 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Safety of vector (del registro, en inglés) (36 meses)

Cómo lo describe el promotor

En el documentoEn inglés, del registroBackground: - Radiation can cause the parotid salivary glands to make less saliva (dry mouth). This can cause problems like infections and tooth decay. Researchers hope a new drug can help people with dry mouth caused by radiation. Objectives: - To examine the safety of AAV2hAQP1 gene therapy. To see if the drug increases saliva in people whose parotid glands have had radiation. Eligibility: - People at least 18 years of age with a history of radiation therapy for head and neck cancer. Design: Participants will be screened in 2 visits with: * medical history * physical exam * scans of the head, neck, and chest * intravenous administration of glycopyrrolate to stop saliva * saliva collections * sialogram which is a procedure in which a substance is injected in the parotid gland and X-rays are taken. * non-drug infusion * a small piece of skin being taken 3-5-day hospital stay: Participants will receive the gene infusion. The AAV2hAQP1 will be in a solution in a syringe. It will be slowly pushed into the parotid gland through the parotid duct, an opening in the mouth near the second upper molar tooth. 10 outpatient visits over 3 years. These may include: * repeats of selected screening tests, including saliva collection * blood and urine tests * oral and dental examinations * head and neck exams, including the use of a thin scope to see the back of the throat * questionnaires * a small piece of parotid tissue being taken by either a small scope through the parotid duct or by a small needle guided by ultrasound * scans of the head and neck. For some, contrast will be injected in a vein * completion of a diary about how the participant feels between visits * swabs of teeth and gums to assess the microbiome of the mouth

Más ensayos de MGTX

EnsayoFaseEstadoLectura de resultados
Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomiano aplicaEn marcha, sin reclutarmar 2027 (prevista)
AAV2-hAQP1 Concentration 1 · AQUAx2Fase 2En marcha, sin reclutarjun 2027 (prevista)
AAV5-hRKp.RPGRFase 3En marcha, sin reclutarjun 2027 (prevista)
AAV5-hRKp.RPGR Intermediate DoseFase 3En marcha, sin reclutarsep 2029 (prevista)
AAV-GADFase 1/2En marcha, sin reclutaroct 2029 (prevista)
AAV5-hRKp.RPGRFase 2En marcha, sin reclutaroct 2030 (prevista)

Todos los de MGTX, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT02446249), actualizada en ago 2026.